Welcome to our dedicated page for Medicinova news (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova stock.
MediciNova, Inc. (MNOV) is a clinical-stage biopharmaceutical company advancing novel therapies for neurodegenerative disorders, fibrotic diseases, and inflammatory conditions. This page serves as the definitive source for verified corporate developments, offering investors and researchers timely access to essential information.
Find comprehensive coverage of MNOV's clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes updates on lead candidates MN-166 (ibudilast) and MN-001 (tipelukast), patent developments, and collaborative research initiatives with academic institutions.
Key content categories include clinical program updates, FDA communications, intellectual property announcements, and financial disclosures. All materials are sourced directly from company filings and official statements to ensure accuracy.
Bookmark this page for streamlined tracking of MNOV's progress in developing small-molecule therapeutics. Check regularly for updates on pipeline advancements in ALS, multiple sclerosis, and fibrotic disease research.
MediciNova, a biopharmaceutical company listed on NASDAQ and Tokyo Stock Exchange, announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering MN-166 (ibudilast) for preventing metastasis in eye cancer. The patent, expected to expire by July 2042, covers the use of MN-166 for uveal melanoma, detailing various doses, frequencies, and treatment periods. MN-166 impedes uveal melanoma migration by inhibiting the macrophage migration inhibitory factor and reducing immune suppressive cells, enhancing CD8 T cell activity. The company views this patent as enhancing the potential value of MN-166 in oncology.
MediciNova announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering MN-166 (ibudilast) for treating chlorine-induced acute respiratory distress syndrome (ARDS). This patent, expected to expire no earlier than January 2042, includes claims for MN-166 as a monotherapy or in combination with other drugs, and covers various administration methods and dosing frequencies. The announcement follows a promising nonclinical model study showing significant improvements in pulmonary function and survival rates with MN-166. Chief Medical Officer Kazuko Matsuda expressed optimism about the potential value this patent adds to MN-166.
MediciNova, Inc. has received a new patent from the U.S. Patent and Trademark Office covering extended-release formulations of MN-166 (ibudilast), set to expire after September 2040. The patent includes claims for tablet or capsule formulations at various doses. Chief Medical Officer, Kazuko Matsuda, sees this patent as enhancing the value of MN-166 by offering patient convenience and potentially reducing side effects.
FAQ
What is the current stock price of Medicinova (MNOV)?
What is the market cap of Medicinova (MNOV)?
